El-Hattab Ayman W, Almannai Mohammed, Sutton V Reid
Division of Clinical Genetics and Metabolic Disorders, Pediatrics Department, Tawam Hospital, Tawam Roundabout, Al-Ain 15258, United Arab Emirates.
Department of Molecular and Human Genetics, Baylor College of Medicine, Texas Children's Hospital, One Baylor Plaza, Houston, TX 77030, USA.
Pediatr Clin North Am. 2018 Apr;65(2):389-405. doi: 10.1016/j.pcl.2017.11.013. Epub 2017 Dec 28.
Newborn screening programs aim to achieve presymptomatic diagnosis of treatable disorders allowing for early initiation of medical care to prevent or reduce significant morbidity and mortality. Many of the conditions included in the newborn screening panels are inborn errors of metabolism; however, screening for endocrine, hematologic, immunologic, and cardiovascular diseases, and hearing loss is also included in many panels. Newborn screening tests are not diagnostic and therefore diagnostic testing is needed to confirm or exclude the suspected diagnosis. Further advancement in technology is expected to allow continuous expansion of newborn screening.
新生儿筛查项目旨在对可治疗疾病进行症状前诊断,以便尽早开始医疗护理,预防或降低严重的发病率和死亡率。新生儿筛查项目所涵盖的许多病症都是先天性代谢缺陷;然而,许多筛查项目也包括对内分泌、血液、免疫和心血管疾病以及听力损失的筛查。新生儿筛查测试并非诊断性测试,因此需要进行诊断性检测来确认或排除疑似诊断。预计技术的进一步发展将使新生儿筛查得以持续扩展。